dPCR and qPCR Market Trends, Growth And Regional Outlook 2027

Quantitative PCR (qPCR) Segment to Grow at Faster CAGR During 2017–2025

According to our new research study on “DPCR and qPCR in Healthcare Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Component, Application, and End User,” the market is expected to reach US$ 6,371.6 million by 2025 from US$ 3,255.5 million in 2017; it is estimated to grow at a CAGR of 9.1% from 2018 to 2025. The report highlights trends prevailing in the market, and the factors driving and hindering the market growth. The growth of the dPCR and qPCRin healthcare market is attributed to the Increasing Incidence of Genetic Diseases, Increase in Investments & Funds for Gene Synthesis, Technological Advancements in PCR Technologies are key drivers for the growth of the market. However, factors such as High Costs of PCR Systems and Technical Limitations Associated with qPCR are likely to restrain the market growth to a certain extent.

Get Free Sample Copy at :

https://www.theinsightpartners.com/SAMPLE/TIPHE100000817/

Based on technology, the dPCR and qPCR in healthcare market is segmented into QPCR and DPCR. The Quantitative PCR (qPCR) held the major market share among the technology segment in 2017, the Quantitative PCR (qPCR) segment held a largest market share of 55.9% of the dPCR and qPCR market, by technology. This segment is also expected to dominate the market in 2025 owing to its improved sensitivity, rapidity and reproducibility. It allows cost effective analysis with inexpensive kits and reagents. Furthermore, the digital PCR segment is anticipated to witness the fastest growth rate during the forecast period, 2018 to 2025.

The dPCR and qPCRin healthcare market is expected to witness substantial growth post-pandemic. The COVID-19 has affected economies and industries in various countries due to lockdowns, travel bans, and business shutdowns. The COVID-19 crisis has overburdened public health systems in many countries and highlighted the strong need for sustainable investment in health systems. As the COVID-19 pandemic progresses, the healthcare industry is expected to see a drop in growth. The life sciences segment thrives due to increased demand for invitro diagnostic products and rising research and development activities worldwide. However, the medical technologies and imaging segment is witnessing drop in sales due to a smaller number of surgeries being carried out and delayed or prolonged equipment procurement. Additionally, virtual consultations by healthcare professionals are expected to become the mainstream care delivery model post-pandemic. With telehealth transforming care delivery, digital health will continue to thrive in coming years. In addition, disrupted clinical trials and the subsequent delay in drug launches is also expected to pave the way for entirely virtual trials in the future. New technologies such as mRNA is expected to emerge and shift the pharmaceutical industry and market is also expected to witness more vertical integration and joint ventures in coming years.

Hoffmann-La Roche Ltd, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Qiagen N.V., Takara Bio, Inc., Agilent Technologies, Inc., Biomérieux S.A., Fluidigm Corporation, Danaher Corporation, and ABBott Laboratories. are among the leading companies operating in the dPCR and qPCRin healthcare market.

The report segments dPCR and qPCR in healthcare market as follows:

By Technology

Quantitative PCR (qPCR)
Digital PCR (dPCR)

By Product

Reagents & Consumables
Instruments
Software & Services

By Application

Research Application
Clinical Application
Forensic Application

By Geography

North America
- US
- Canada
- Mexico
Europe
- France
- Germany
- UK
- Spain
- Italy
- Rest of Europe
Asia Pacific (APAC)
- China
- India
- Japan
- Australia
- South Korea
- Rest of APAC
Middle East & Africa (MEA)
- Saudi Arabia
- UAE
- South Africa
- Rest of MEA
South and Central America (SCAM)
- Brazil
- Argentina
- Rest of SCAM